"The prostamides are part of a large and continually expanding series of pharmacologically unique neutral lipids. Prostamide pharmacology is unique and, as in the case of the endocannabinoids anandamide and 2-arachidonylglycerol, bears little resemblance to that of the corresponding free acids. By virtue of its close relationship to the anti-glaucoma drug bimatoprost, prostamide F2a has received the greatest research attention. Prostamide F2a and bimatoprost effects appear independent of prostanoid FP receptor activation, according to a litany of agonist studies. Studies...revealed that bimatoprost and FP receptor agonists stimulated different cells, without exception. This suggests the existence of receptors that preferentially recognize prostamide F2a. The recent discovery of prostamide antagonists has provided further support for prostamide receptors as discrete entities. The prototypical prostamide antagonists, AGN 204396 and 7, blocked the effects of prostamide F2a and bimatoprost but not those of PGF2a and FP receptor agonists in the feline iris. Second generation more potent prostamide antagonists, such as AGN 211334, should allow the role of prostamides in health and disease to be elucidated. From the therapeutics standpoint, the prostamide F2a analogue bimatoprost is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma.
British Journal of Pharmacology (2008) 153, 410–419.
Sem comentários:
Enviar um comentário